Long-term outcomes of image-guided ablation and laparoscopic partial nephrectomy for T1 renal cell carcinoma

Vinson Wai-Shun Chan 1 · Filzah Hanis Osman 1 · Jon Cartledge 2 · Walter Gregory 3 · Michael Kimuli 2 · Naveen S. Vasudev 4 · Christy Ralph 6 · Satinder Jagdev 4 · Selina Bhattarai 5 · Jonathan Smith 6 · James Lenton 6 · Tze Min Wah 6

Abstract
Objective  To compare long-term outcomes and peri-operative outcomes of image-guided ablation (IGA) and laparoscopic partial nephrectomy (LPN).

Material and methods  This is a retrospective cohort study of localised RCC (T1a/bN0M0) patients undergoing cryoablation (CRYO), radio-frequency ablation (RFA), or LPN at our institution from 2003 to 2016. Oncological outcomes were compared using Cox regression and log-rank analysis. eGFR changes were compared using Kruskal-Wallis and Wilcoxon-rank tests.

Results  A total of 296 (238 T1a, 58 T1b) consecutive patients were identified; 103, 100, and 93 patients underwent CRYO, RFA, and LPN, respectively. Median follow-up time was 75, 98, and 71 months, respectively. On univariate analysis, all oncological outcomes were comparable amongst CRYO, RFA, and LPN (p > 0.05). On multivariate analysis, T1a patients undergoing RFA had improved local recurrence-free survival (LRFS) (HR 0.002, 95% CI 0.00–0.11, p = 0.003) and metastasis-free survival (HR 0.002, 95% CI 0.00–0.52, p = 0.029) compared to LPN. In T1a and T1b patients combined, both CRYO (HR 0.07, 95% CI 0.01–0.73, p = 0.026) and RFA (HR 0.04, 95% CI 0.03–0.48, p = 0.011) had improved LRFS rates. Patients undergoing CRYO and RFA had a significantly smaller median decrease in eGFR post-operatively compared to LPN (T1a: p < 0.001; T1b: p = 0.047). Limitations include retrospective design and limited statistical power.

Conclusions  IGA is potentially as good as LPN in oncological durability. IGA preserves kidney function significantly better than LPN. More studies with larger sample size should be performed to establish IGA as a first-line treatment alongside LPN.

Key Points
• Ablative therapies are alternatives to partial nephrectomy for managing small renal cell carcinomas.
• This study reports long-term outcomes of image-guided ablation versus partial nephrectomy.
• Ablative therapies have comparable oncological durability and better renal function preservation compared to partial nephrectomy.

Keywords  Cryoablation · Image-guided ablation · Partial nephrectomy · Radio-frequency ablation · Renal cell carcinoma
Abbreviations

(L)PN (Laparoscopic) Partial Nephrectomy
AUA American Urological Association
CCI Charlson comorbidity index
CRYO Cryoablation
CSS Cancer-specific survival
EAU European Association of Urology
IGA Image-guided ablation
LRFS Local recurrence-free survival
MFS Metastasis-free survival
OS Overall survival
RCC Renal cell carcinoma
RFA Radio-frequency ablation
SRM Small renal mass

Introduction

Traditionally, patients with small renal masses (SRMs) are managed by radical or partial nephrectomies (PNs). However, laparoscopic PNs (LPNs) are associated with significant complication rates (~20%) [1]. Percutaneous image-guided radio-frequency ablation (RFA) in SRMs was first reported in 1997 [2]. The adoption of image-guided ablation (IGA) has rapidly increased in the management of SRMs due to its minimally invasive nature and the theoretical ability to offer preservation of renal function and lower complication rate when compared to PN [3]. Other energy sources have been adopted to manage SRMs, including cryoablation (CRYO) [4], microwave ablation [5], and, more recently, irreversible electroporation [6].

The current European Association of Urology (EAU) guidelines suggest strong evidence to perform PN for T1 renal masses, and weak evidence to only offer IGA to those with significantly co-morbidity and frailty [7]. The EAU guidelines have also suggested IGA to be associated with higher rates of recurrence, although unlikely after 5 years, based on limited evidence [7]. On the other hand, the American Urological Association (AUA) guidelines suggest thermal ablation as an alternative approach in managing cT1a tumours; however, the lack of high-quality literature with long follow-up periods of patients with confirmed histology was emphasised [8]. The AUA guidelines also specify the importance of long follow-up periods (> 5 years) to accurately assess for late local recurrences. While there are some non-randomised evidence base to perform PN over radical nephrectomy, there is only one study by Andrews et al, showing comparable long-term oncological outcomes of IGA and LPN for SRMs for up to 5 years[3, 9]. Chang et al, had also shown comparable 5-year outcomes between laparoscopic or imaged-guided RFA and PN [10]. Furthermore, the overall quality of studies comparing IGA and LPN is limited. Single-arm studies have suggested effective long-term cancer control in patients undergoing percutaneous RFA at 10 years [11].

While there is a desperate need for a high-quality randomised controlled trial to compare RFA, CRYO, and LPN, prospective recruitment has proven to be difficult as seen by the SURAB feasibility study and the CONSERVE trial, which both failed in recruitment [12, 13]. This study aims to provide 10 years of experience and evidence to inform guidelines for long-term oncological outcomes in patients undergoing image-guided CRYO or RFA and LPN for biopsy- or histology-proven T1aN0M0 and T1bN0M0 renal cell carcinomas (RCCs).

Methods

Study design

This is a retrospective analysis of a prospectively maintained registry from 2003 to 2016. Following institutional health and research authority approval, consecutive adult patients who underwent image-guided CRYO, RFA, or laparoscopic LPN for cT1N0M0 histology-confirmed RCC were included for the study. The patient selection process at our institution was previously described [14]. cT1 renal masses were defined as a maximum tumour diameter of \( \leq 7 \) cm limited to the kidney on radiographic imaging according to the American Joint Committee on Cancer staging manual [15]; with cT1 further divided to cT1a (\( \leq 4 \) cm) and cT1b (> 4 cm and \( \leq 7 \) cm). Patients presenting with multiple renal tumours, recurrence, inherited RCC syndromes, or a solitary kidney were excluded from the analysis [16]. Patients with a history of LPN, CRYO, or RFA of the same kidney were also excluded from analysis. Primary outcome of the study was to evaluate and compare the long-term local recurrence-free survival (LRFS) between CRYO, RFA, and LPN. Secondary outcomes include overall survival (OS), cancer-specific survival (CSS), metastasis-free survival (MFS), rate and severity of complications, and change in renal function peri-operatively. The detailed methods of the performance of IGA and LPN are outlined in the supplementary appendix.

Patient follow-up

The follow-up protocol for IGA was previously described in detail [14]. All patients were followed at 1, 3, and 6 months after the procedure and annually onwards for a period of 10 years using MRI or CT. Local recurrence was defined as new area(s) of enhancement in the zone of ablation after at least one imaging study had shown complete lack of enhancement in the treated area. Metastatic disease was defined as extra-renal disease on imaging confirmed or suspicioned to have
originated from the kidney. Cancer-specific death was defined as any deaths from RCC.

Clinical features, variables, covariates, and data acquisition

Patient clinical features such as age, sex, treatment date, follow-up details, histopathological details, R.E.N.A.L. nephrometry score [17], co-morbidities (according to the Charlson Comorbidity Index [CCI][18]), procedure details, complications (according to the Clavien Dindo Classification [19]), and estimated glomerular filtration rate (eGFR; CKD-EPI [20]) were extracted from the prospectively maintained database. Utilising the National Health Service (NHS) patient records, the patients were followed for their living status and cause of death until 25th January 2021.

Outcomes and data synthesis

Differences in baseline characteristics were evaluated using the chi-square test and the Kruskal-Wallis test. CSS, OS, LRFS, and MFS were evaluated from the time of treatment to the time of event using the Kaplan-Meier method. Ten-year survival rates and corresponding 95% confidence intervals (95% CI) were reported. The Cox proportional hazards regression model was utilised to evaluate survival in CRYO, RFA, and LPN patients, reporting as hazard ratios (HRs), 95% CI, and $p$-values. To allow evaluation of HRs when no events were observed in an arm, an event was artificially created at the latest follow-up for that arm. Complication rates and severity were evaluated using the chi-squared test and logistic regression. Changes in peri-operative renal function were evaluated using the Kruskal-Wallis test and the Wilcoxon matched pairs signed rank sum test. Propensity score was imputed. Sensitivity analyses have shown identical results and hence all patients were included in the final analyses. All analyses are two-tailed at a significance level of 0.05. All statistical analyses were performed on STATA/MP 16.0 (StataCorp).

Results

A total of 290 patients were included in the analysis. Supplementary figure 1 shows how these patients were selected for inclusion in the study.

Oncological outcomes in T1a patients using univariate analysis

Baseline characteristics of T1a patients

A summary of the clinical and pathological characteristics of the 238 T1a patients included in the analysis is given in Table 1. RCC histology, Fuhrman grade, age, tumour size, R.E.N.A.L. nephrometry score, baseline eGFR and CCI were found to be significantly different between the three groups. The median (IQR) follow-up time was 75.6 (66.8–86.5) months, 106.0 (61.2–135.1) months, and 72 (64.6–99.7) months in CRYO, RFA, and LPN patients, respectively.

Event-specific outcomes

Totals of 204, 238, 233, and 233 patients were evaluated for CSS, OS, LRFS, and MFS, respectively, with exclusions being for lack of follow-up (LRFS: 5, MFS: 5), and unknown causes of death (CSS: 4) in the LPN group only. Results were comparable between the 3 groups for all 4 endpoints (Figs. 1 and 2). Only two RCC-related deaths were observed: one in the RFA group and one in the LPN group. A total of 31 deaths were observed (CRYO: 13, RFA: 9, LPN: 9). Ten local recurrences were observed (CRYO: 2, RFA: 5, LPN: 3). Five metastatic events were observed (CRYO: 0, RFA: 2, LPN: 3). A total of 72 and 87 patients were evaluated for CRYO and RFA for all outcomes, respectively. A total of 75, 79, 74, and 74 patients undergoing LPN were evaluated for CSS, OS, LRFS, and MFS, respectively.

Oncological outcomes in T1b patients on univariate analysis

A summary of their clinical and pathological characteristics are outlined in Table 2. RCC histology, Fuhrman grade, age, tumour size, R.E.N.A.L. nephrometry score, baseline eGFR, and CCI were found to be significantly different between the three
groups. The median (IQR) follow-up duration is 72.5 (42.0–100.9) months, 59.5 (27.5–99.3) months, and 67.9 (50.8–91.3) months for CRYO, RFA, and LPN, respectively. CSS, OS, LRFS, and MFS are all comparable between patients undergoing CRYO, RFA, or LPN (Figs. 1 and 3). The details of the results are outlined in the supplementary appendix.

Post-operative complications

The rate and severity of post-operative complications for all three modalities were found to be similar in both cT1a (CRYO: 11.1%, RFA: 18.4%, LPN: 14.1%) and cT1b patients (CRYO: 19.4%, RFA: 15.4%, LPN: 7.7%). Both logistic regression and multinomial logistic regression did not show significant difference between the three groups’ rate and severity of complications (Supplementary Table 1 and 2). A summary of all complications occurring during the study period are reported in Supplementary Table 3.

Change in renal function

The post-operative eGFR and change in eGFR peri-operatively of T1a and T1b patients undergoing CRYO, RFA, and LPN are shown in Table 3. Only small changes in eGFR were found in patients undergoing CRYO and RFA, as compared to substantial falls in eGFR in LPN patients (Wilcoxon matched pairs signed rank sum Z and p-values; CRYO: 3.0, 0.003, RFA: 2.4, 0.02, LPN: 6.0, < .0001). When comparing the change in renal function peri-operatively using the Wilcoxon 2-sample rank sum test, in both T1a (Z = 4.1, p < .0001) and T1b (Z = 2.5, p = .01) patients, those undergoing IGA had a significantly smaller median change in eGFR compared to LPN (Table 3).

Results of propensity-score matching and multivariate analysis

Initially, it was intended to explore the propensity score matching approach, as described in the “Methods” section. However, this proved to be infeasible due to large differences in baseline factors between the treatment groups, most substantially in age (Supplementary Figure 4; Tables 1 and 2). Further details, results, and explanation are given in supplementary Figures 2 and 3. Therefore, as described in the “Methods” section, the Cox multivariate method was used to adjust for these imbalances and compare the treatment arms.
**Fig. 1** Forest plot summary of all oncological outcomes in T1a and T1b patients undergoing cryoablation or RFA compared to LPN using the univariate Cox proportional hazard model; 95% CI, 95% confidence interval; CSS, cancer-specific survival; OS, overall survival; LRFS, local recurrence-free survival; MFS, metastasis-free survival; RFA, radio-frequency ablation; LPN, partial nephrectomy.

| Outcome (PN) | CSS (T1a) | OS (T1a) | LRFS (T1a) | MFS (T1a) | CSS (T1b) | OS (T1b) | LRFS (T1b) | MFS (T1b) |
|--------------|-----------|----------|------------|-----------|-----------|----------|------------|-----------|
| Cryoablation | 1.45 [0.66, 2.40] | 1.78 [0.76, 4.18] | 0.74 [0.12, 4.47] | 0.30 [0.03, 2.98] | 0.96 [0.06, 14.4] | 0.90 [0.36, 2.28] | 1.20 [0.28, 5.10] | 0.53 [0.09, 3.19] |
| RFA          | 0.68 [0.04, 11.46] | 2.33 [0.78, 6.95] | 0.11 [0.08, 2.02] | 0.66 [0.04, 11.18] | 1.22 [0.08, 19.86] | 2.12 [0.59, 7.52] | 0.39 [0.04, 3.77] | 0.87 [0.05, 13.94] |

**Fig. 2** a) Cancer-specific survival, b) overall survival, c) local recurrence-free survival, and d) metastasis-free survival in T1a patients.
As events are relatively scarce in this study, sensitivity analyses were performed by replacing an event with censoring at that time (results not presented). Minimal differences to the results presented were observed for all of the outcomes, demonstrating that the results are relatively insensitive to such small changes, and are therefore relatively robust. Certainly, the overall findings would be unchanged as a result of a single patient having a different outcome.

In univariate Kaplan-Meier analyses, IGA and LPN were shown to have comparable LRFS. However, given that the CRYO and RFA groups consist of patients with considerably worse prognostic factors, after multivariate adjustment, CRYO and RFA appear to be superior to LPN for LRFS. The magnitude of the effect in the two ablative therapy groups is almost identical (see Supplementary Figure 5) so a combined group analysis, stratified by group, was performed, demonstrating ablative therapies to be superior to LPN for LRFS (HR 0.006, 95% CI 0.00–0.15, \( p = 0.002 \)). Note that the RFA/LPN comparison reaches statistical significance on its own (Table 4; \( p = 0.003 \)), and, although the CRYO/LPN result is not statistically significant (Table 4, \( p = 0.087 \)), this is largely a result of paucity of patient and event numbers. Although effect sizes (HR) appear to be substantial for statistically significant outcomes (LRFS, MFS), suggesting extreme advantage to IGA patients, they are unlikely to reflect real effect sizes due to a combination of the extreme selection bias. Finally, the lower 90% confidence interval on the hazard ratio is less than 1 for CRYO (Supplementary Table 5), which demonstrates at least 90% confidence that CRYO is as good as LPN for LRFS. For clarity, characteristics of all patients with T1a tumours and subsequent local recurrences are shown in Table 5.

**Discussion**

The number of high-quality studies comparing the use of IGA and LPN is scarce, with most limited by extreme selection bias and short follow-up periods [3, 24]. The univariate analysis results hereby reported are similar to that reported by Andrews et al [9] in 2019 and a recent published meta-analysis [3] as CSS, LRFS, and MFS were found to be comparable amongst the three modalities in both T1a and T1b patients. However, the available studies only

### Table 2 Baseline characteristics of T1b patients

| Modality          | Cryoablation \((n = 31)\) | RFA \((n = 13)\) | PN \((n = 14)\) |
|-------------------|-----------------------------|------------------|------------------|
| **Variable**      | Frequency %                 | Frequency %      | Frequency %      | \( p \)-value |
| Sex               |                             |                  |                  |              |
| Male              | 22 29.1                      | 6 46.2           | 6 42.9           | \( p = 0.897 \) |
| Female            | 9 71.0                       | 7 53.9           | 8 57.14          |              |
| Laterality        |                              |                  |                  |              |
| Left              | 15 48.4                      | 2 15.4           | 9 64.3           | \( p = 0.656 \) |
| Right             | 16 59.7                      | 11 84.6          | 5 35.7           |              |
| Horsehoe          | 0 0.0                        | 0 0.0            | 0 0              |              |
| RCC type          |                              |                  |                  | \( p < 0.001 \) |
| Conventional      | 24 77.4                      | 12 100.0         | 12 85.7          |              |
| Papillary         | 2 6.5                        | 0 0              | 1 7.1            |              |
| Oesinophil        | 0 0                          | 0 0              | 1 7.1            |              |
| Chromophobe       | 5 16.1                       | 0 0              | 0 0              |              |
| Fuhrman grade     |                              |                  |                  | \( p < 0.001 \) |
| Ungraded          | 2 6.45                       | 2 15.4           | 2 14.3           |              |
| 1                 | 4 12.9                       | 2 15.4           | 2 14.3           |              |
| 2                 | 19 61.3                      | 6 46.2           | 2 14.3           |              |
| 3                 | 5 16.1                       | 3 23.1           | 8 57.1           |              |
| 4                 | 1 3.2                        | 0 0              | 0 0              |              |
| Age               | Median 77.0 IQR 65–80        | Median 78 IQR 65–79 | Median 57 IQR 44–67 | \( p < 0.001 \) |
| Tumour size (cm)  | 4.5 Median 4.10–5.10 IQR 4.5 | 4.5 Median 4.5–4.8 IQR 4.45 | 4.2–5.3 | \( p = 0.001 \) |
| R.E.N.A.L nephrometry score | 9 Median 7–10 IQR 7 | 7 Median 7–9 IQR 7 | 5–8 | \( p = 0.002 \) |
| Baseline eGFR     | 57.6 Median 42.8–79.2 IQR 37.3 | 37.3 Median 30.5–43.4 IQR 84.8 | 73.3–97.1 | \( p < 0.001 \) |
| Charlson Comorbidity Index | 4 Median 3–6 IQR 2.5–4.0 | 3 Median 0.5–4.5 IQR 0.5–4.5 | 3 Median 0.5–4.5 IQR 0.5–4.5 | \( p < 0.001 \) |
assessed outcomes up to 5 years. In this cohort, as a result of serious selection bias, where LPN patients are significantly younger and less comorbid and have smaller tumours, propensity score matching was impossible. Therefore, a multivariate Cox proportional hazards model approach was utilised. In the multivariate analysis, we have found all oncological outcomes are at least comparable. Although LRFS is shown to be superior in T1a and T1b patients undergoing RFA \((p=0.011)\) and CRYO \((p=0.026)\), given the small number of events, model sensitivity issues, and the fact that this is not a randomised trial, it is perhaps inappropriate to think that the results demonstrate superiority for ablative therapies. However, it seems reasonable to conclude that IGAs are at least as good as the surgical alternative. Furthermore, in contrast to the EAU’s guidance [7], our results have shown that recurrences after 5 years may have been more common than usually perceived, with five recurrences observed after 5 years (Table 5).

Despite selection bias, in contradiction to previous cohorts [9, 25] and a recent meta-analysis [3], our study did not find OS to be significantly different in the three treatment arms in both T1a and T1b patients. Andrews et al have reported 5-year OS to be significantly worse in CRYO and RFA patients with T1a/T1b disease even after propensity matching and subgroup analysis in patients with RCC [9]. The positive finding in our study could be the result of the extended follow-up time, offsetting potential selection bias arising over age of the included

### Table 3  Peri-operative change in eGFR in T1a and T1b patients undergoing image-guided cryoablation, RFA, and PN

| Outcome                        | T-stage | Cryoablation | RFA | PN       | \(p\)-value (Kruskal-Wallis test) |
|--------------|---------|--------------|-----|---------|-----------------------------|
| Pre-operative eGFR (ml/min/1.73 m²; median [IQR]) | T1a     | 77.88 (60.9–87.8) | 89.0 (71.2–104.4) | 91.3 (75.3–101.9) | <0.001 |
|                 | T1b     | 57.6 (42.8–79.2)  | 37.3 (30.5–43.4)  | 84.8 (73.3–97.1)  | <0.001 |
| Post-operative eGFR (ml/min/1.73 m²; median [IQR]) | T1a     | 68.9 (52.9–85.7)  | 88.5 (70.6–100.82) | 75.2 (60.4–92.0)  | <0.001 |
|                 | T1b     | 56.4 (34.1–77.8)  | 40.0 (27.8–49.9)  | 61.5 (44.2–80.0)  | <0.001 |
| Change in eGFR pre-and post-operatively (ml/min/1.73 m²; median [IQR]) | T1a     | -1.39 (-7.51–1.28) | -2.42 (-9.1–3.8)  | -7.40 (-18.1 to -2.8) | <0.001 |
|                 | T1b     | -2.11 (-7.6–1.1)  | -1.52 (-2.7–2.2)  | -13.3 (-39.9 to -1.1) | 0.078 |
| Percentage change in eGFR pre- and post-operatively (%) (median [IQR]) | T1a     | -2.19 (-11.2)  | -3.44 (-10.0–4.6) | -9.35 (-22.5 to -3.00) | <0.001 |
|                 | T1b     | -5.05 (-15.6–1.4) | -1.70 (-9.4–5.9)  | -24.6 (-41.9 to -11.3) | 0.047 |

*RFA*, radio-frequency ablation; *PN*, partial nephrectomy; *eGFR*, estimated glomerular filtration rate; *IQR*, interquartile range
patients. Furthermore, life expectancy in the UK is significantly higher than that in the USA, further offsetting the age selection bias in the study [26]. While age is commonly regarded as a confounder in similar studies, our study found it to be a significant, but only small predictor of overall survival in patients with T1a tumours in this cohort (HR 1.05, 95% CI 1.01–1.08, \( p = 0.016 \)), explaining the minimal effect of selection bias on our results.

The rate and severity of complications in our study was not significantly different amongst the three modalities. This is in line with recent studies and with the meta-analysis of percutaneous IGA and PN [3]. While no theoretical advantage of reduced complications is observed in the literature, the learning curve for both LPN and percutaneous IGA is at about 100 cases [14, 27, 28], and few results have been reported for centres significantly beyond the learning curve [3].

### Table 4

| Modality                  | Cryoablation | RFA | Cryoablation and RFA combined |
|---------------------------|--------------|-----|-------------------------------|
| Outcome                   | HR (95% CI)  | p-value | HR (95% CI)  | p-value | HR (95% CI)  | p-value |
| T1a only                  |              |       |                               |         |               |         |
| CSS                       | Not estimated* | 0.708 | Not estimated* | 0.657 | 0.66 (0.19–2.39) | 0.544 |
| OS                        | 1.30 (0.33–5.11) | 0.707 | 0.70 (0.15–3.34) | 0.657 | 0.0001 (0.00–7876.7) | 0.323 |
| LRFS                      | 0.003 (0.00–2.39) | 0.087 | 0.002 (0.00–0.11) | 0.003 | 0.006 (0.00–0.15) | 0.002 |
| MFS                       | Not estimated* |       | 0.002 (0.00–0.52) | 0.029 | 0.002 (0.00–0.51) | 0.028 |
| T1a and T1b               |              |       |                               |         |               |         |
| CSS                       | Not estimated* | 0.613 | Not estimated* | 0.426 | 0.08 (0.01–0.44) | 0.004 |
| OS                        | 1.20 (0.47–3.59) | 0.073 | 0.62 (0.19–2.03) | 0.462 | 0.73 (0.30–1.77) | 0.487 |
| LRFS                      | 0.07 (0.01–0.73) | 0.026 | 0.04 (0.03–0.48) | 0.011 | 0.08 (0.01–0.44) | 0.004 |
| MFS                       | Not estimated* |       | 0.19 (0.01–3.10) | 0.242 | 0.13 (0.01–2.22) | 0.158 |

*RFA, radio-frequency ablation; HR, hazard ratio; CSS, cancer-specific survival; OS, overall survival; LRFS, local recurrence-free survival; MFS, metastasis-free survival

*Not estimated due to the limited number of events

### Table 5

| Intervention | Age | Sex | Laterality | CCI | Pre-operative eGFR | Tumour grade | R.E.N.A.L. nephrometry score | Lesion size | RCC type | LRFS duration (months) | Outcome                        |
|--------------|-----|-----|------------|-----|---------------------|--------------|-------------------------------|-------------|----------|------------------------|--------------------------------|
| Cryoablation | 74  | Male| Right      | 6   | 56.7                | 2            | 8                             | 3.6         | Clear cell | 52                     | Dead unrelated to RCC          |
| RFA (mean)   | 75  | Male| Right      | 5.5 | 68.07               | 2            | 7.5                           | 3.15        | Chromophobe | 64                     | Alive                          |
| RFA          | 68  | Male| Right      | 4   | 103.2               | 3            | 8                             | 3.3         | Clear cell | 54                     | Alive                          |
| RFA          | 78  | Female| Left   | 3   | 78.4                | 3            | 9                             | 3.5         | Clear cell | 54                     | Alive                          |
| RFA          | 77  | Female| Right  | 3   | 52.2                | 3            | 7                             | 2.7         | Clear cell | 111                    | Alive                          |
| RFA          | 83  | Male| Right     | 6   | 121.5               | 1            | 9                             | 3.3         | Clear cell | 52                     | Alive                          |
| RFA (mean)   | 73  | Female| Left  | 4   | 75.6                | 3            | 8                             | 3           | Clear cell | 78                     | Alive                          |
| PN           | 65  | Female| Left   | 2   | 79.7                | 3            | 9                             | 1.8         | Clear cell | 64                     | Alive                          |
| PN           | 64  | Male | Left     | 4   | 74.5                | 3            | 4                             | 3.4         | Clear cell | 88                     | Alive                          |
| PN           | 65  | Male| Right    | 3   | 93.3                | 3            | 7                             | 3.4         | Clear cell | 8                      | Dead from RCC                  |
| (PN mean)    | 64.7|      |          | 3   | 82.5                | 3            | 6.7                           | 2.87        |          | 53.3                   |                                |
| Overall mean | 72.3|      |          | 3.8 | 81.4                | 2.3          | 7.6                           | 3.07        |          | 62.4                   |                                |
As expected, as renal paranchyma is better preserved in CRYO and RFA, our study found little or no change in eGFR in patients undergoing CRYO and RFA, as compared to a significant fall of eGFR in LPN patients. Although not investigated in this study, this will help inform treatment decisions in those with solitary kidneys or impaired renal function. The strengths of this study include long-term follow-up, inclusion of R.E.N.A.L nephrometry scores and confirmed RCC status. While the results may be positive, this study does not come without its limitations. Firstly, our sample size (especially with T1b patients) is too small to be well-powered statistically. Secondly, the study is also limited by strong selection bias owing to the retrospective study design. This is evident by the inability to perform propensity score matching, with attempted mitigation using multivariate analysis. However, despite the selection bias, the results are still positive. Thirdly, it is recognised that treatment options may depend on the location of the tumour and the nephrometry score may not be a complete representation of tumour complexity for treatment. Ultimately, it may not be entirely safe to treat central tumours with CRYO, RFA, or even LPN, and radical nephrectomy may remain an option for some of the patients. Finally, the inclusion of only LPN may not be representative of patients undergoing robotic PN or open PN, as complication profiles and oncological outcomes may significantly differ [29].

The optimal investigations and management of small RCCs are debated, and there are factors that must be taken into consideration in order to compile evidence to allow better patient care. For example, the use of renal tumour biopsies should be considered, at least in a research context, as this allows evaluation of the treatment effects of malignant lesions without the biases arising from a proportion of benign results [30, 31]. The use of active surveillance to manage small RCCs is becoming increasingly popular [32, 33], and the use of renal tumour biopsy prior to both active surveillance and IGA will allow for better comparison between the different management of small RCCs.

This study reported long-term outcomes of patients undergoing CRYO, RFA, or LPN for T1a/T1b RCC. Although, in this cohort, patients undergoing CRYO and RFA have superior LRFS and comparable oncological outcome in general, the extreme selection bias and lack of events suggest the cautious conclusion that CRYO and RFA are at least as good as LPN in oncological outcomes. However, this study can conclude that CRYO and RFA have better renal function preservation compared to LPN. Therefore, percutaneous IGA, CRYO, and RFA should be potentially reflected in guidelines to be considered first-line treatment along with LPN for small RCCs providing more promising outcomes from larger prospective and multicentre cohorts can be made available evaluating both the peri-operative and long-term outcomes for both T1a and T1b RCCs. The highly anticipated NEST trial [34], a RCT comparing LPN and IGA in T1a is designed to address the much needed level one evidence in this area.

### Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1007/s00330-022-08719-1.

### Declarations

**Guarantor** The scientific guarantor of this publication is Vinson Wai-Shun Chan and Tze Min Wah.

**Conflict of interest** The authors of this manuscript declare relationships with the following companies:
- Research Grant – Boston Scientific
- Education Grant – Angiodynamics

**Statistics and biometry** Prof. Walter Gregory kindly provided statistical advice for this manuscript, he has significant statistical expertise.

**Informed consent** Written informed consent was waived by the Institutional Review Board.

**Ethics approval** Institutional Review Board approval was not required because of the retrospective nature of the study.

**Methodology**
- Retrospective
- Observational
- Performed at one institution

### Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

### References

1. Lowrance WT, Yee DS, Savage C et al (2010) Complications after radical and partial nephrectomy as a function of age. J Urol 183:1725–1730. https://doi.org/10.1016/j.juro.2009.12.101
2. Zlotta AR, Wildschutz T, Raviv G et al (1997) Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J Endourol 11:251–258. https://doi.org/10.1089/end.1997.11.251
3. Chan VW-S, Abul A, Osman FH et al (2022) Ablative therapies versus partial nephrectomy for small renal masses – a systematic review and meta-analysis. Int J Surg 97:106194. https://doi.org/10.1016/j.ijsu.2021.106194
4. Georgiades CS, Rodriguez R (2014) Efficacy and safety of percutaneous cryoablation for stage I A/B renal cell carcinoma: results of a prospective, single-arm, 5-year study. Cardiovasc Intervent Radiol 37:1494–1499. https://doi.org/10.1007/s00270-013-0831-8
5. Thompson SM, Schmitz JJ, Thompson RH et al (2018) Introduction of microwave ablation into a renal ablation practice: valuable lessons learned. AJR Am J Roentgenol 211:1381–1389. https://doi.org/10.2214/ajr.18.19775
6. Wah TM, Lenton J, Smith J et al (2021) Irreversible electroperoration (IRE) in renal cell carcinoma (RCC): a mid-term clinical experience. Eur Radiol. 1–9. https://doi.org/10.1007/s00330-021-08746-5

7. B Ljungberg L, Bensalah K, Bex A et al (2020) EAU Guidelines: Renal Cell Carcinoma | Uroweb. EAU Guidelines Office, Arnhem, The Netherlands. http://uroweb.org/guidelines/compilations-of-all-guidelines/. Available via https://uroweb.org/guideline/renal-cell-carcinoma. Accessed 15 Aug 2020

8. Campbell S, Uzzo Robert G, Allaf Mohamad E et al (2017) Renal mass and localized renal cancer: AUA guideline. J Urol 198:520–529. https://doi.org/10.1016/j.juro.2017.04.100

9. Andrews JR, Atwell T, Schmitt G et al (2019) Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 76:244–251. https://doi.org/10.1016/j.eururo.2019.04.026

10. Chang X, Liu T, Zhang F et al (2015) Radiofrequency ablation versus partial nephrectomy for clinical T1a renal-cell carcinoma: long-term clinical and oncologic outcomes based on a propensity score analysis. J Endourol 29:518–525. https://doi.org/10.1089/end.2014.0864

11. Marshall HR, Shakiri S, Hosseiny M et al (2020) Long-term survival after percutaneous radiofrequency ablation of pathologically proven renal cell carcinoma in 100 patients. J Vasc Interv Radiol 31:15–24. https://doi.org/10.1016/j.jvir.2019.09.011

12. Soomro N, Lecouturier J, Stocken DD et al (2017) Surveillance versus ablation for incidentally diagnosed small renal tumours: the SURAB feasibility RCT. Health Technol Assess 21:1–68. https://doi.org/10.3310/hta21810

13. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier: NCT01608165, A feasibility study for a multicentre randomised controlled trial to compare surgery with needle ablation techniques in people with small renal masses (4cm) (CONSERVE); 30 May 2012 [cited 11 Sept 2020]; [about 4 screens]. Available online: https://clinicaltrials.gov/ct2/show/NCT01608165

14. Wah TM, Irving HC, Gregory W, Cartledge J, Joyce AD, Selby PJ (2014) Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int 113:416–428. https://doi.org/10.1111/bju.12349

15. Amin MB, Greene FL, Edge SB et al (2017) The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. Cancer J Clin 67:93–99. https://doi.org/10.3322/caac.21388

16. Chan VW-S, Lenton J, Smith J et al (2021) Multimodal image-guided ablation on management of renal cancer in Von-Hippel-Lindau syndrome patients from 2004 to 2021 at a specialist centre: a longitudinal observational study. Eur J Surg Oncol. https://doi.org/10.1016/j.ejso.2021.10.022

17. Kutikov A, Uzzo RG (2009) The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantifying renal tumor size, location and depth. J Urol 182:844–853. https://doi.org/10.1016/j.juro.2009.05.035

18. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8

19. Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae

20. Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612. https://doi.org/10.7326/0003-4819-150-9-20090505-00006

21. Austin PC (2014) The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 33:1242–1258. https://doi.org/10.1002/sim.5984

22. Edwin L, Barbara S (2003) PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing, S432001. Boston College Department of Economics

23. Cox DR (1972) Regression models and life-tables. Journal of the Royal Statistical Society: Series B (Methodological) 34:187–202. https://doi.org/10.1111/j.2517-6161.1972.tb00899.x

24. Abu-Ghanem Y, Fernández-Pello S, Bex A et al (2020) Limitations of available studies prevent reliable comparison between tumour ablation and partial nephrectomy for patients with localised renal masses: a systematic review from the European Association of Urology Renal Cell Cancer Guideline Panel. Eur Urol Oncol 3: 433–452. https://doi.org/10.1016/j.euo.2020.02.001

25. Covin B, Benoit T, Delchier Marie C et al (2019) MP42-10 long term trifecta outcomes of partial nephrectomy versus percutaneous ablation in CT1A renal masses. J Urol 201:e610-e610. https://doi.org/10.1097/01.jju.0000565213.96797.89

26. Wang H, Abbas KM, Abbasisfar M et al (2020) Global age-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet 396:1160–1203. https://doi.org/10.1016/S0140-6736(20)30977-6

27. Breen DJ, Bryant TJ, Abbas A et al (2013) Percutaneous cryoablation of renal tumours: outcomes from 171 tumours in 147 patients. BJU Int 112:758–765. https://doi.org/10.1111/bju.12122

28. Porpiglia F, Bertolo R, Amparore D, Fiori C (2013) Margins, ischaemia and complications rate after laparoscopic partial nephrectomy: impact of learning curve and tumour anatomical characteristics. BJU Int 112:1125–1132. https://doi.org/10.1111/bju.12317

29. Crocerossa F, Carbonara U, Cantiello F et al (2021) Robot-assisted radical nephrectomy: a systematic review and meta-analysis of comparative studies. Eur Urol 80:428–439. https://doi.org/10.1016/j.eururo.2020.10.034

30. Richard PO, Jewett MA, Bhatt JR et al (2015) Renal tumor biopsy of renal tumours: outcomes from 171 tumours in 147 patients. BJU Int 112:758–765. https://doi.org/10.1111/bju.12122

31. Chan VW-S, Keeley FX, Lagerveld B et al (2022) The changing trends of active surveillance for young patients with small renal masses: prospective data from the DISSRM Registry. J Urol 205:1578–1587. https://doi.org/10.1111/j.1524-1341.2020.14347.x

32. Abu-Ghanem Y, Fernández-Pello S, Bex A et al (2020) Limitations of available studies prevent reliable comparison between tumour ablation and partial nephrectomy for patients with localised renal masses: a systematic review from the European Association of Urology Renal Cell Cancer Guideline Panel. Eur Urol Oncol 3: 433–452. https://doi.org/10.1016/j.euo.2020.02.001

33. Cox DR (1972) Regression models and life-tables. Journal of the Royal Statistical Society: Series B (Methodological) 34:187–202. https://doi.org/10.1111/j.2517-6161.1972.tb00899.x

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.